Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#3004 Development of Anti-SSTR CAR T Cells for Future Treatment of NETs
Introduction: NETs overexpress somatostatin receptors (SSTRs).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Cives M
Authors: Mandriani B, Cives M, Pelle' E, Quaresmini D, Ramello M,
Keywords: CAR T cells, adoptive cellular immunotherapy, NETs,
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Mpilla G
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, Philip P,
Keywords: pak4, nampt, mtor, pancreatic neuroendocrine tumors, kpt-9274,
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Yao J, Fazio N, Li D, Pavel M, Strosberg J,
Keywords: PDR001, immunotherapy, NET,
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti-PD-1 and anti-PD-L1, have become established treatment (tx) options in various solid tumors. However, there is a paucity of data on checkpoint inhibitors in NET. In a phase I trial of PDR001 (mAb checkpoint inhibitor targeting PD-1) conducted in patients (pts) with multiple solid tumor types, a pt with histologically confirmed metastatic atypical pulmonary carcinoid demonstrated a RECIST-based tumor response and clinical benefit.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Yao J
Authors: Yao J, Fazio N, Pavel M, Strosberg J, Bergsland E,
Keywords: PDR001, immunotherapy, NET,
Introduction: Lung cancer is the main cause of cancer death. Non small cell lung cancer (NSCLC) cause about 85% of cases and small cell lung cancer (SCLC) represents 15%. Therapy resistance is commonly related with a transformation from adenocarcinoma to SCLC. SCLC shows neuroendocrine (NE) features and exhibits aggressive behavior. In vitro production of vasopressin (AVP) was reported in SCLC. The AVP V1 receptors are associated with mitogenic signaling pathways, while AVP V2 receptor (V2r) is related with an opposite effect. DDAVP is a synthetic analog of AVP that acts as a selective agonist for V2r. DDAVP displays cytostatic and antimetastatic properties in breast and colorectal cancer. In our laboratory a new analog, [V4Q5]dDAVP, showed improved cytostatic activity
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: